The global TAM for treatment of diabetes is massive. US equity markets have a lot of experience valuing continuous glucose monitoring (CGM) device makers such as the market leader, Dexcom (NYSE; DXCM);
- The global TAM for CGM device makers is c. US$5bn with cagr c.11%.
- DXCM current mkt value = US$35bn, equating to a revenue multiple of about x35!!!
- The point is, US equity markets go bananas over diabetes treatment innovation due to huge TAM, cagr and IP protection.
For the treatment of DFU's;
- TAM of US$7bn and likely c.10% cagr
- The application of Synpath to DFU's is a sleeping giant under the sp of PNV.
- Forums
- ASX - By Stock
- PNV
- Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial
Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial, page-51
Featured News
Add PNV (ASX) to my watchlist
|
|||||
Last
$2.34 |
Change
-0.030(1.27%) |
Mkt cap ! $1.616B |
Open | High | Low | Value | Volume |
$2.41 | $2.43 | $2.32 | $5.953M | 2.536M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 29039 | $2.33 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.35 | 16702 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4000 | 2.330 |
7 | 38855 | 2.310 |
9 | 44383 | 2.300 |
1 | 2068 | 2.290 |
5 | 18946 | 2.280 |
Price($) | Vol. | No. |
---|---|---|
2.360 | 2068 | 1 |
2.370 | 2068 | 1 |
2.380 | 2068 | 1 |
2.390 | 2068 | 1 |
2.400 | 2068 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online